Researchers say this net loss is unlikely to reverse without state and federal policy changes, including PBM reform.
News|Articles|November 8, 2004
NCPA's new Rx benefit model to rival PBMs
Instead of merely complaining about the tactics of pharmacy benefit managers, the National Community Pharmacists Association is working on a game plan to take the Rx drug benefit play away from their arch enemies.
Advertisement
Advertisement
Related to this article
At the center of the debate are the growing number of manufacturer demands for claims data as a condition of 340B pricing.
Nicholas Rebold, PharmD, MPH, BCIDP, AAHIVP, discusses his team’s and patients’ experiences in a pharmacist-led antiretroviral initiative.
Zaid Fadul, MD, FS, FAAFP, introduces the Nolla Derm app, what it might mean for pharmacists and their patients, and where AI prescribing is headed in the future.
Among a collection of patients across 15 pharmacies, researchers assessed acceptability and satisfaction with pharmacist-led clinical services.
From expert sources and recent data updates to a look at cases amid the ongoing respiratory virus season, this is an updated look at 2026 measles outbreaks in the US.
Zaid Fadul, MD, FS, FAAFP, joins for part 2 to discuss what greater adoption of AI across health care ecosystems might mean for pharmacists, patients, and more.
For pharmacies competing with CVS and relying on Caremark to serve patients, the prospect of those businesses operating under separate ownership is significant.
Advertisement
Advertisement
Trending on Drug Topics
1
US Lost Over 3000 Pharmacies From 2022 to 2024, Mostly Chains
2
CVS Plans to Split Off Its Retail Pharmacies, Keeping Specialty Operations
3
How Pharmacist-Led ART Protocol Improves HIV Medication Outcomes
4
Measles Cases Near 5000 in 2026 as Flu Season Starts Earlier Than Usual
5